New Two-Drug attack on tough lung cancer
NCT ID NCT03527108
Summary
This study is testing whether combining two existing drugs, nivolumab and ramucirumab, can help control advanced lung cancer that has grown again after a patient's prior immunotherapy. It will enroll 36 adults with this specific type of cancer to see if the combination is safe and can stop the cancer from growing. The main goal is to measure the 'disease control rate,' which includes patients whose tumors shrink or stop growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
NYU Langone
New York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.